AI assistant
GlaxoSmithKline PLC — Remuneration Information 2020
May 26, 2020
5262_def-14a_2020-05-26_8d6d51ca-af19-42c5-b457-82d19817e417.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
RNS Number : 9474N
GlaxoSmithKline PLC
26 May 2020
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan | |||
| Period of return: | From: | 1 November 2019 | To: | 30 April 2020 |
| Balance of unallotted securities under scheme(s) from previous return: | 153,724 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 370,000 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 388,348 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 135,376 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares | |||
| Period of return: | From: | 1 November 2019 | To: | 30 April 2020 |
| Balance of unallotted securities under scheme(s) from previous return: | 835,095 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 581,004 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 254,091 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline 2009 Share Option Plan - ADS | |||
| Period of return: | From: | 1 November 2019 | To: | 30 April 2020 |
| Balance of unallotted securities under scheme(s) from previous return: | 5,391,416 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 698,736 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 4,692,680 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc Share Save Plan 2012 | |||
| Period of return: | From: | 1 November 2019 | To: | 30 April 2020 |
| Balance of unallotted securities under scheme(s) from previous return: | 2,145,812 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 698,407 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,447,405 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BLRDZGZKGVLGGZM